On April 26, 2023 Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported the acceptance of multiple abstracts for poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which is taking place in Chicago from June 2-6, 2023 (Press release, Mersana Therapeutics, APR 26, 2023, View Source [SID1234630536]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follows:
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers
Abstract Number: TPS3154
Presenter: Erika Hamilton, MD, Director, Breast Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology
Session Track & Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Session Date & Time: June 3 from 8:00-11:00 a.m. CT
Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC)
Abstract Number: 5545
Presenter: Debra Richardson, MD, Associate Professor, Obstetrics & Gynecology and Section Chief of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Session Track & Title: Poster Session – Gynecologic Cancer
Session Date & Time: June 5 from 1:15-4:15 p.m. CT
UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upifitamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer
Abstract Number: TPS5614
Presenter: Debra Richardson, MD, Associate Professor, Obstetrics & Gynecology and Section Chief of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Session Track & Title: Poster Session – Gynecologic Cancer
Session Date & Time: June 5 from 1:15-4:15 p.m. CT
UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
Abstract Number: TPS5613
Presenter: John Hays, MD, PhD, Assistant Professor, Department of Internal Medicine, Division of Medical Oncology, The Ohio State University
Session Track & Title: Poster Session – Gynecologic Cancer
Session Date & Time: June 5 from 1:15-4:15 p.m. CT